Treating acute myeloid leukemia among children with down syndrome

Abstract

Background: Down Syndrome (DS) children with acute myeloid leukemia (AML) have unique differences in clinical features, epidemiologic nature, and biologic patterns of disease compared with AML in children without DS. Aims and Objective: AML in DS children should be considered distinct disorder from AML in Non DS population and treatment needs to be customized for this population. In this retrospective study spanning from 2014 to 2019 we present our experience of managing leukemia in children with DS. Materials and Methods: From 2014 and 2019, 72 children aged below 18 years were managed at our institute with acute myeloid leukemia (AML). Out of these 72 children with AML, 7 children were with DS which was confirmed by karyotyping. Majority of these children had M7 while M2 and M4 subtypes were seen in one child each. On conventional karyotyping in addition to trisomy 21 additional cytogenetic abnormalities were seen in 4 patients. Two children had trisomy 8. One child had deletion of 11 chromosomes and one had translocation between 8 and 21 chromosomes. Results: All 7 children were administered intensive chemotherapy with curative intent after informed parental consent. All 7 children achieved complete remission. Four out of 7 children had complications related to severe neutropenia. Conclusion: All patients of DS with AML should be offered chemotherapy with curative intent. Endeavour should be to give less aggressive chemotherapy protocol to bring down treatment related mortality.

Keywords

Acute myeloid leukemia - curative intent - Down syndrome

Publication History

Received: 20 April 2020

Accepted: 19 August 2020

Article published online:
14 May 2021

• References

• 1 Amayreh A, Al QaqaK, Ali AH, Issa K. Clinical and cytogenetic profile of down syndrome at king hussein medical centre. JRMS 2012; 19: 14-8
• 2 Mitelman F, Heim S, Mandahl N. Trisomy 21 in neoplastic cells. Am J Med Genet Suppl 1990; 7: 262-6
• 3 Falini B, Tiacci E, Martelli MP, Ascani S, Pileri SA. New classification of acute myeloid leukemia and precursor-related neoplasms: Changes and unsolved issues. Discov Med 2010; 10: 281-92
• 4 Lange B. The management of neoplastic disorders of haematopoiesis in children with Down'ssyndrome. Br J Haematol 2000; 110: 512-24
• 5 Hama A, Yagasaki H, Takahashi Y, Nishio N, Muramatsu H, Yoshida N. et al. Acute megakaryoblasticleukaemia (AMkL) in children: Acomparison of AMkL with and without Down syndrome. Br J Haematol 2008; 140: 552-61
• 6 Abildgaard L, Ellebaek K, Gustafsson G, Abildgaard L, Ellebaek E, Gustafsson G. et al Optimal treatment intensity in children with downsyndrome and myeloid leukaemia: Data from 56 children treated on NOPHO-AML protocols and areview of the literature. Ann Hematol 2006; 85: 275-80
• 7 Taga T, Shimomura Y, Horikoshi Y, Ogawa A, Itoh M, Okada M. et al. Continuous and high-dose cytarabine combinedchemotherapy in children with down syndrome and acute myeloid leukemia: Report from theJapanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study. Pediatr Blood Cancer 2011; 57: 36-40
• 8 Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le BeauMM. et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32: 148-52
• 9 Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer 2008; 112: 416-32
• 10 Howlader N, Howlader A, Krapcho MS, Noone AM, Neyman N, Aminou R. et al. SEER cancer statistics review, 1975-2009 (vintage 2009 populations).
• 11 Arora RS, Arora B. Acute leukemia in children: A review of the current Indian data. South Asian J Cancer 2016; 5: 155-60
• 12 Radhakrishnan V, Thampy C, Ganesan P, Rajendranath R, Ganesan TS, Rajalekshmy KR. et al. Acute myeloid leukemia in children: Experience from tertiary cancer centre in India. Indian J Hematol Blood Transfus 2016; 32: 257-61
• 13 Kulkarni KP, Marwaha RK. Childhood acute myeloid leukemia: An Indian perspective. Pediatr Hematol Oncol 2011; 28: 257-68
• 14 Seth R, Pathak N, Singh A, Chopra A, Kumar R, Kalaivani M. Pediatric acute myeloid leukemia: Improved survival rates in India. Indian J Pediatr 2017; 84: 166-7
• 15 Arora RS, Pizer B, Eden T. Understanding refusal and abandonment in the treatment of childhood cancer. Indian Pediatr 2010; 47: 1005-10
• 16 Kapoor R, Mathews V, Sengar M, Bhurani D, Radhakrishnan V, Philip C. et al. Hematological cancer consortium: Multi-center acute myeloid leukemia registry data from India. Blood 2018; 132 (Suppl 1): 4006
• 17 Caldwell JT, Ge Y, Taub JW. Prognosis and management of acute myeloid leukemia in patients with Down syndrome. Expert Rev Hematol 2014; 7: 831-40
• 18 Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M. et al. Acute myeloid leukemia (AML) in down's syndrome is highly responsive to chemotherapy: Experience on pediatric oncology group AML Study 8498. Blood 1992; 80: 2210-4
• 19 Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L. et al. Favorable survival maintained in children who have myeloid leukemia associated with down syndrome using reduced-dose chemotherapy on children's oncology group trial A2971: A report from the children's oncology group. Cancer 2012; 118: 4806-14
• 20 Uffmann M, Rasche M, Zimmermann M, Neuhoff CV, Creutzig U, Dworzak M. et al. Therapy reduction in patients with Down syndrome and myeloid leukemia: The international ML-DS 2006 trial. Blood 2017; 129: 3314-21
• 21 Lehrnbecher T, Zimmermann M, Reinhardt T, Dworzak M, Stary J, Creutzig U. et al. Prophylactic human granulocyte colony-stimulating factor after induction therapy in Pediatric acute myeloid leukemia. Blood 2007; 109: 936-43
• 22 Lohmann DJ, Asdahl PH, Abrahamsson J, Ha SY, Jónsson ÓG, Kaspers GJL. et al Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01. Pediatr Blood Cancer 2019; 66: e27701
• 23 Feng X, Lan H, Ruan Y, Li C, Sarin YK. Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: A meta-analysis. Hematology 2018; 23: 581-9
• 24 Gurion R, Belnik-Plitman Y, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I. et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev 2012; 6: CD008238
• 25 Von Neuhoff C, Reinhardt D, Sander A, Bradtke J, Betts DR, Zemanova Z. et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010; 28: 2682-9
• 26 Blink M, Zimmermann M, von Neuhoff C, Reinhardt D, Haas V, Hasle H. et al. Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: A retrospective, international study. Haematologica 2014; 99: 299-307